Heart failure after allogeneic hematopoietic stem cell transplantation.

Xiao-Dong Mo,Lan-Ping Xu,Dai-Hong Liu,Xiao-Hui Zhang,Huan Chen,Yu-Hong Chen,Wei Han,Yu Wang,Feng-Rong Wang,Jing-Zhi Wang,Ting Zhao,Chen-Hua Yan,Yu-Qian Sun,Kai-Yan Liu,Xiao-Jun Huang

DOI: https://doi.org/10.1016/j.ijcard.2012.06.021

IF: 4.039

2013-01-01

International Journal of Cardiology

Abstract:Heart failure (HF) occurring after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rare but severe. We examine the role of pre-HSCT therapeutic exposures, conditioning regimens, pre-HSCT comorbidities, severe transplant-related complications, and post-HSCT cardiovascular risk factors in the development of heart failure after allo-HSCT.A nested case-control study was designed. Cases with HF and controls matched for age, year of allo-HSCT, and length of follow-up were identified from a cohort of 2455 patients who underwent allo-HSCT between 2000 and 2011 for hematologic malignancies.Forty-two patients suffered from HF; mean age at presentation was 35 years (± 14 years) and mean time to presentation was 5 months (± 9 months) post-HSCT. The number of pre-HSCT cycles of chemotherapy was significantly greater (7 vs. 5 courses, P=0.023). Cases were significantly more likely to have severe acute GVHD (≥ grade III), hemorrhagic cystitis (≥ grade 2), and multiple severe transplant-related complications compared with controls (42.9% vs. 20.4%, P=0.008). Multivariate analysis revealed that pre-HSCT cycles of chemotherapy of ≥ 5 courses (OR=3.5, P=0.003) and two or more severe transplant-related complications (OR=3.6, P=0.003) were independently associated with HF.These results identify the individuals who are at higher risk of developing HF after allo-HSCT. We should pay more attention to these patients and more active management would be reasonable.